IHF:NYE-iShares U.S. Healthcare Providers ETF (USD)

ETF | Health |

Last Closing

USD 56.54

Change

-0.03 (-0.05)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.51 (+0.33%)

USD 42.10B
FHLC Fidelity® MSCI Health Care In..

+0.25 (+0.35%)

USD 3.01B
FXH First Trust Health Care AlphaD..

+0.83 (+0.75%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

+0.22 (+0.25%)

USD 0.23B
IDNA iShares Genomics Immunology an..

+0.24 (+0.98%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.12 (+0.31%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

+0.57 (+0.60%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.52 (+1.80%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.58 (+0.93%)

USD 0.02B
FTXH First Trust Nasdaq Pharmaceuti..

+0.04 (+0.13%)

USD 0.02B

ETFs Containing IHF

LCR Leuthold Core ETF 4.21 % 0.00 %

+0.14 (+0.40%)

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.67% 41% F 47% F
Dividend Return 0.58% 53% F 11% F
Total Return 8.26% 45% F 41% F
Trailing 12 Months  
Capital Gain 13.55% 18% F 44% F
Dividend Return 0.82% 53% F 10% F
Total Return 14.37% 18% F 39% F
Trailing 5 Years  
Capital Gain 76.64% 100% F 79% B-
Dividend Return 4.77% 58% F 15% F
Total Return 81.42% 100% F 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 9.24% 90% A- 67% D+
Dividend Return 9.87% 81% B- 62% D
Total Return 0.63% 63% D 15% F
Risk Return Profile  
Volatility (Standard Deviation) 16.94% 57% F 59% D-
Risk Adjusted Return 58.26% 71% C- 76% C+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:

There is nothing we particularly dislike